Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03383458 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT03383458 · ClinicalTrials.gov record · last posted 2026-07-31

A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation

Name: A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation — clinical trial record (NCT03383458)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: CheckMate 9DX

StatusActive, Not Recruiting

PhasePhase 3

SponsorBristol-Myers Squibb

Started2018-04-18

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This study will investigate if nivolumab will improve recurrence-free survival (RFS) compared to placebo in participants with HCC who have undergone complete resection or have achieved a complete response after local ablation, and who are at high risk of recurrence

Protocol amendment history 2 changes detected by DataLookout

2026-08-01

Primary completion pushed: 2026-02-27 → 2026-05-27

2026-08-01

Completion pushed: 2031-02-27 → 2031-05-27

Trial Details

NCT Number	NCT03383458
Lead Sponsor	Bristol-Myers Squibb Collaborators: Ono Pharmaceutical Co., Ltd.
Conditions	Hepatocellular Carcinoma, Liver Cancer
Enrollment	545 participants
Start Date	2018-04-18
Primary Completion	2026-05-27 (estimated)
Study Completion	2031-05-27 (estimated)
Updated on ClinicalTrials.gov	2026-07-31